“Pilavapadin, an oral, non-opioid, AAK1 inhibitor for diabetic peripheral neuropathic pain (DPNP): results from a Phase 2b, dose-ranging, randomized, placebo-controlled, multicenter study” was ...

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that ...

Mayo Clinic researchers have developed a new way to predict whether existing drugs could be repurposed to treat heart failure ...

A majority of cancer drugs approved in the US during 2019-2022 had “clinical trial uncertainties,” research suggests.

The CORE-MD (Coordinating Research and Evidence for high-risk Medical Devices) consortium has published new consensus ...

Discover how a new data-driven technology is revolutionizing prosthetic leg design. A recent UK study shows that this ...